Council to discuss letter regarding Amtrak funding
The letter, addressed to Sens. Chuck Grassley and Joni Ernst, as well as Reps. Marianette Miller-Meeks and Zach Nunn, discusses concerns about the potential lack of funding as part of the next federal budget.
Amtrak, which is subsidized by the government, operates the California Zephyr, one of two long-distance trains that runs through Iowa. Ottumwa is one of the stops on the route, which stretches from Chicago to Emeryville, California, near San Francisco.
However, without financial support, the route could be discontinued under U.S. Code if Congress fails to provide funding for train service. So far, the Trump Administration has not indicated if there will be funding available.
"Amtrak has not submitted a grant request for FY 2026 yet and has signaled it may not submit one at all," Johnson said in his letter. "It is critical that Amtrak be funded in 2026 so they can continue to operate their passenger trains across southern Iowa.
"Amtrak is a key component of economic vitality in southern Iowa and the number of travelers using Amtrak continues to increase every year as airplane travel becomes more restricted and more expensive."
Ottumwa was the third-most popular stop in Iowa according to Amtrak's most recent figures from fiscal year 2024. The Ottumwa stop featured 8,719 riders, and the only two stops with higher ridership were Osceola (13,194) and Mount Pleasant (9,128), which bracket the Ottumwa stop to the west and east, respectively, on the California Zephyr.
Also, Amtrak has been reconstructing the depot's platform and other making other improvements to the station since 2022, which initially cost about $14 million.
"Without Amtrak service to and from Ottumwa, the results would be catastrophic to both our local economy as well as reduced tourism travel across southern Iowa," Johnson said in the letter.
Also, the council is expected to establish fees for various permits, which will be effective July 1.
The meeting begins at 5:30 p.m.
Wapello County Board of Supervisors
The supervisors will meet in regular session Tuesday at the courthouse to discuss minor items, but will later enter a work session to discuss the makeup of the EMS advisory council, which was tabled two weeks ago amid frustration over favoritism from City of Ottumwa officials, who were concerned the council wasn't constructed to meet the community's needs.
The regular meeting begins at 9:30 a.m. in the third-floor courtroom/board room, but the work session will be at 10 a.m. in the supervisors' office on North Court Street.
Two weeks ago, the supervisors adopted a resolution to declare EMS as an essential county service, which was also intended to kickstart the creation of the advisory council and the work to begin assessing the county's needs.
However, the creation of the list was tabled for more discussion over concerns regarding the representation, specifically the lack of law enforcement officials among the 14 council members.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
Key Points Johnson & Johnson and Novartis are facing (or will soon face) important patent cliffs. Both companies can handle these challenges thanks to their deep lineups and innovative abilities. Both drugmakers also have excellent dividend-paying stocks. 10 stocks we like better than Johnson & Johnson › Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar competition that erodes their market share. Although these sometimes threaten drugmakers, some can effectively handle the challenge and perform relatively well. With that as a backdrop, let's discuss two pharmaceutical leaders that have faced (or will face) patent expiration for some of their most important products, but should be able to overcome the threat: Johnson & Johnson (NYSE: JNJ) and Novartis (NYSE: NVS). 1. Johnson & Johnson In July 2024, Johnson & Johnson began facing biosimilar competition for Stelara, an immunology medicine and one of its best-selling products, in Europe. The same thing occurred in the U.S. in February of this year. The result is that Stelara's sales are dropping off a cliff. In the second quarter, the medicine generated revenue of $1.7 billion -- a 42.7% decrease from the same period last year. Still, Johnson & Johnson continues to post solid financial results. Its top line in the period grew by 5.8% year over year to $23.7 billion. J&J even raised both top- and bottom-line guidance for the year. In other words, the company is performing relatively well, despite the drop in sales for Stelara. J&J has an incredibly diversified business with a long list of medicines in its pharmaceutical segment. Some of its top growth drivers include cancer medicines Darzalex and Erleada, as well as Remicade, which treats several immunology conditions. The company also has newer products in its arsenal: Imaavy for myasthenia gravis (a condition that causes muscle weakness) was approved earlier this year, and it's awaiting word from regulators for TAR-200, a highly promising investigational medicine for bladder cancer. Furthermore, Johnson & Johnson is a leading player in the medical device industry. One long-term growth driver for the company could be its robotic-assisted surgery system, the Ottava, which is still undergoing clinical trials in the U.S. J&J can overcome patent cliffs -- and, for that matter, drug-price negotiations that also threaten its business -- through innovation. That's what the company is doing with Stelara, and it can do so in the future. Finally, Johnson & Johnson is a terrific dividend stock; it's raised its payouts for 62 consecutive years, making it a Dividend King. The company can handle all the challenges it faces and still deliver solid returns over the long run. 2. Novartis Novartis is gearing up for generic competition for Entresto, a medication for heart failure, later this year in the U.S. Through the first half of the year, this drug generated $4.6 billion in sales, almost 52% of which came from the U.S. With cheaper generics in its single most important market for its best-selling medicine, Novartis might be in trouble -- except it isn't. The drugmaker continues to expect high-single-digit revenue growth for the year, a strong performance for a pharmaceutical giant. Even if Entresto's patent cliff has a greater impact on financial results next year, the company should be fine. Novartis has a vast and diversified portfolio of medicines across various therapeutic areas. Many of its products are blockbusters; seven had already generated more than $1 billion in revenue each through the first six months of 2025. Novartis also has several newer products that will help drive top-line growth for a long time. For instance, in April the company earned U.S. approval for Vanrafia, a medicine indicated to treat proteinuria (excess protein in urine) in patients with a rare kidney disease called IgA nephropathy. Some analysts estimate that Vanrafia could hit peak sales of $1.5 billion. Novartis' extensive lineup, combined with its continued launches of new products, should help it move beyond Entresto's patent cliff. Additionally, the company is engaged in patent litigation over the legitimacy of generic versions of Entresto. If it ends up winning these battles, it might be owed money from companies that would have launched those generics on the market. Even if that doesn't happen, the drugmaker should continue delivering consistent revenue and earnings over the long run, as well as annual dividend increases. The company has raised its payouts for 28 consecutive years. Despite the patent-cliff threat it faces, Novartis remains a top pick for those seeking blue chip dividend stocks. Should you invest $1,000 in Johnson & Johnson right now? Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy. Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm was originally published by The Motley Fool
Axios
8 hours ago
- Axios
Amtrak begins new service between New Orleans, Mobile
For the first time since Hurricane Katrina, an Amtrak conductor in New Orleans shouted "all aboard!" as passengers loaded up a Mobile-bound train on Saturday. Why it matters: The Mardi Gras line links New Orleans with four other Gulf Coast towns between it and Alabama, a move that city and state officials will boost tourism and business opportunities along that stretch while, they hope, proving regional rail can thrive in the Deep South. State of play: Tickets for the train's first day of return to public service on Monday sold out, a spokesman says, and Saints game days already appear popular for future dates. A key for Amtrak growth means having more of a presence beyond the Northeast," company president Roger Harris tells Axios New Orleans. Amtrak expects to release its 2024 fiscal reports soon, which Harris says will show record ridership. "One of the missions we're on is to make sure rail transportation is available in a convenient way to greater parts of the country," he says. Amtrak hopes the Mardi Gras line's return jumpstarts that, especially with the service's existing routes that already connect New Orleans to places like Chicago and Houston. "Transportation is a network function," Harris says. "That is important: getting that critical mass together in any one area is that self-reinforcing activity." Zoom in: Saturday's inaugural ride was filled with about 300 Amtrak guests, including local and state politicians, tourism boosters and New Orleans Mardi Gras royalty. They boarded in time for an 8am send-off complete with a brass band led second-line and showers of purple, green and gold confetti. The train made each of what'll be its usual stops in in Bay St. Louis, Gulfport, Biloxi, Pascagoula, though this time with marching bands and waving crowds at each before a final lunchtime bash in Mobile. The vibe: As the view outside fell away from New Orlean suburbs, the train on Saturday chugged under and over bridges and through stretches of marshland, beachfront, open water and, eventually, forested thickets before landing at the edge of Mobile's port. It's a stunning ride that far outpaces the view from I-10 without any of its traffic. Plus, it has snacks, WiFi and plenty of legroom. (The quarter muffuletta was an especially pleasant surprise, with a tangy olive salad and soft, sesame seed-studded breaded.) The line itself is still undergoing some key improvements, a spokesman says, which for now require a few slowdowns below its top speed of 79 mph. That means service along the route will only get faster. How it works: Tickets start at $15, with discounts available for seniors, groups, kids, veterans and military personnel. Departures are planned from each stop twice daily. What's next: Local leaders and Amtrak officials hope the long-promised train route between New Orleans and Baton Rouge soon becomes a reality that leads to a rail expansion between metro areas across the state. The needed replacement of a trestle bridge over the Bonnet Carre spillway remains a sticking point, Harris says. "We need to use this as a launching pad to get the rail to Baton Rouge and to Shreveport and across North Louisiana," Lt. Gov. Billy Nungesser said Saturday. "We've got an incredible opportunity. ... If we can't get it done with (House Majority Leader) Steve Scalise and (Speaker of the House) Mike Johnson, it'll never get done."
Chicago Tribune
19 hours ago
- Chicago Tribune
Waukegan Community Unit School District 60 receiving additional revenue from state's evidence-based funding program
As Gwen Polk prepares the budget she will present to the Waukegan Community Unit School District 60 Board of Education in September, she has learned that she has approximately $6.2 million in additional revenue courtesy of the State of Illinois' evidence-based funding program. Though every school district receives some of the $9.25 billion appropriated by the Illinois General Assembly, Tier 1 districts like Waukegan and North Chicago School District 187 face a harder time adequately funding education, including a smaller property tax base, and receive the most. When the Illinois General Assembly approved the final $350 million in May — $43 million was held for distribution at a later time — Lake County's 13 Tier 1 districts and the Regional Office of Education were awarded 87.5% of the county's total, with District 60 getting 38% — $6.2 million. Polk, District 60's associate superintendent for business and financial services, said the proposed budget currently sits at slightly less than $327 million. With COVID-19 federal relief funds no longer available, the additional money from the state is a big help. 'We're all affected by the fiscal cliff,' Polk said, referring to the federal money schools received nationwide. 'The increase (from the state) is going to help.' Lake County's 47 school districts and the Regional Office of Education collectively received just under $16.3 million in additional evidence-based funding earlier this month from the state, bringing its total to more than $562 million to augment their budgets. For the Waukegan public schools, Polk said evidence-based funding provides for more than half of its total revenue, which also includes property tax income. The approximate district-wide enrollment for the 2025-2026 school year is 14,000. By contrast, Barrington Community Unit School District 220, a Tier 4 district — they receive the smallest amount of evidence-based funding — with approximately 8,100 students, received just over $6.5 million. State Sen. Adriane Johnson, D-Buffalo Grove, said evidence-based funding became law in Illinois in 2017 to help all schools get to a level of funding to adequately educate youngsters. 'Education is the great equalizer,' Johnson said, 'If students' schools are adequately funded they they get the support and resources they need. This helps students in low-income areas get those resources.' Originally proposing $550 million for the final round of evidence-based funding, Johnson said that with a tight state budget, $350 million was the most she and her colleagues could get passed. In Waukegan, like most school districts, the bulk of the budget goes toward salaries and benefits for teachers, staff, and administrators. The current evidence-based funding is 4.1% more than a year ago, but not close to full adequacy. With the largest share of evidence-based funding in Lake County, District 60's adequacy level is 72%, well below the ideal amount. Barrington's adequacy level is 119%. Some of the highest adequacy levels are found where the property values are also high. Leading Lake County in adequacy is Rondout School District 72 at 255% which includes parts of Lake Forest, Lake Bluff, Green Oaks, and Mettawa. Bannockburn School District 106 is at 202% while Lake Forest High School District 115 is at 193% and Township High School District 113 serving Deerfield and Highland Park High Schools is at 190%. District 187 Principal John Price said the adequacy level in North Chicago dropped from 78% to 71%. A year ago, there was a large influx of migrant children that is not the case this year. The district is receiving $1.67 million, the second-highest amount in Lake County. Price said District 187's budget is approximately $80 million, and its evidence-based funding totals just under $40.1 million.
